GH Research’s stock rallied after saying the FDA lifted a hold on its experimental depression treatment.
Source: MarketWatch
Wednesday, 07. January 2026
Share:
05. January 2026 15:01
A small company can now advance its psychedelic into Phase 3. Here’s why that matters to other psychedelic biotechs.
